Midesteine

Midesteine

SCHEMBL724755

CC(SC(=O)c1cccs1)C(=O)NC1CCSC1=O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
ELANE P08246 2/20 1.00
MAPK1 P28482 2/20 0.59
ALDH1A1 P00352 3/20 0.52
CYP1A2 P05177 1/20 0.49
KMT2A Q03164 3/20 0.47
MEN1 O00255 2/20 0.47
NPSR1 Q6W5P4 1/20 0.46
HSD17B10 Q99714 1/20 0.46
POLB P06746 1/20 0.45
HPGD P15428 2/20 0.43
GAA P10253 1/20 0.43
SMN1; SMN2 Q16637 2/20 0.42
TP53 P04637 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9356448 0.90 ELANE (0.81) ELANEMAPK1ALDH1A1CYP1A2KMT2A
SCHEMBL10588348 0.80 ELANE (0.66) ELANEMAPK1ALDH1A1CYP1A2KMT2A
SCHEMBL11113900 0.79 MAPK1 (0.78) ELANEMAPK1ALDH1A1CYP1A2KMT2A
SCHEMBL13954060 0.77 ELANE (0.63) ELANEALDH1A1CYP1A2KMT2AMEN1
SCHEMBL21007472 0.76 CYP1A2 (0.73) ELANEALDH1A1CYP1A2KMT2AMEN1
SCHEMBL14521500 0.76 CYP1A2 (0.73) ELANEALDH1A1CYP1A2KMT2AMEN1
SCHEMBL11189007 0.75 ELANE (0.59) ELANEALDH1A1KMT2AMEN1HPGD
SCHEMBL11189010 0.75 ELANE (0.59) ELANEALDH1A1KMT2AMEN1HPGD
SCHEMBL10589123 0.73 ELANE (0.58) ELANEMAPK1POLB
SCHEMBL10589133 0.73 ELANE (0.57) ELANEMAPK1ALDH1A1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 209 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260130899-A1 METHOD OF TREATMENT FOR PREVENTION OF GLUCOCORTICOID TOXICITY AND/OR ENHANCEMENT OF MUSCLE REGENERATION VIA NEUTROPHIL ELASTASE INHIBITION THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) 2026-05-14 US claimed
US-20250064792-A1 MUSCLE REGENERATION THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) 2025-02-27 US claimed
US-20240216353-A1 METHOD OF TREATMENT FOR PREVENTION OF GLUCOCORTICOID TOXICITY AND/OR ENHANCEMENT OF MUSCLE REGENERATION VIA NEUTROPHIL ELASTASE INHIBITION THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) 2024-07-04 US claimed
US-20230127290-A1 MUSCLE REGENERATION THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) 2023-04-27 US claimed
US-20210315873-A1 METHOD OF TREATMENT FOR PREVENTION OF GLUCOCORTICOID TOXICITY AND/OR ENHANCEMENT OF MUSCLE REGENERATION VIA NEUTROPHIL ELASTASE INHIBITION THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) 2021-10-14 US claimed
US-20210196694-A1 MUSCLE REGENERATION THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) 2021-07-01 US claimed
US-20190134014-A1 MUSCLE REGENERATION THE UNIVERSITY OF LIVERPOOL (GB) 2019-05-09 US claimed
CN-105085428-B Aromatic heterocyclic derivatives and its application on drug 广东东阳光药业有限公司 2019-03-22 CN claimed
CN-106279138-B Aromatic heterocyclic derivatives and its application in drug 广东东阳光药业有限公司 2019-03-01 CN claimed
CN-109248319-A Contain the pharmaceutical composition for taking charge of smooth class compound and aspirin 郜建敏 2019-01-22 CN claimed
CN-107157976-A Application of the compound of thioether acids structure in medicament for resisting platelet aggregation is prepared 北京北朋科技有限公司 2017-09-15 CN claimed
CN-106279138-A Heteroaromatic analog derivative and the application in medicine thereof 广东东阳光药业有限公司 2017-01-04 CN claimed
CN-105399698-A Aromatic heterocyclic derivatives and applications of aromatic heterocyclic derivatives in medicines GUANGDONG HEC PHARMACEUTICAL 2016-03-16 CN claimed
WO-2016034134-A1 HETEROAROMATIC DERIVATIVES AND PHARMACEUTICAL APPLICATIONS THEREOF SUNSHINE LAKE PHARMA CO., LTD. (CN) 2016-03-10 WO claimed
CN-105085428-A Heteroaromatic derivative and application thereof to medicament GUANGDONG HEC PHARMACEUTICAL 2015-11-25 CN claimed
WO-2015161830-A1 HETEROAROMATIC DERIVATIVES AND PHARMACEUTICAL APPLICATIONS THEREOF SUNSHINE LAKE PHARMA CO., LTD. (CN) 2015-10-29 WO claimed
CN-101330905-A Freeze-drying process and products obtained thereby SCIDOSE LLC (US) 2008-12-24 CN claimed
EP-1336602-A1 Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases Scaramuzzino, Giovanni (IT) 2003-08-20 EP claimed
US-4481212-A RESPIRATORY SYSTEM DISORDERS MEDEA RESEARCH S.R.L. (IT) 1984-11-06 US claimed
EP-0120534-A1 Thiolactic acid derivative with bronchosecretolitic activity MEDEA RESEARCH S.r.l. (IT) 1984-10-03 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260130899-A1 METHOD OF TREATMENT FOR PREVENTION OF GLUCOCORTICOID TOXICITY AND/OR ENHANCEMENT OF MUSCLE REGENERATION VIA NEUTROPHIL ELASTASE INHIBITION SERPINB1, ELANE, CELA1 ELANE 2/4885MAPK1 762/4885ALDH1A1 3318/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.